Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials
Open accessThe DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Abstract
Chemotherapy is one of the most established and effective treatments for almost all types of cancer. However, the elevated toxicity due to the non-tumor-associated effects, development of secondary malignancies, infertility, radiation-induced fibrosis and resistance to treatment limit the effectiveness and safety of treatment. In addition, these multiple factors significantly impact quality of life. Over the last decades, our increased understanding of cancer epigenetics has led to new therapeutic approaches and the promise of improved patient outcomes. Epigenetic alterations are commonly found in cancer, especially the increased expression and activity of histone deacetylases (HDACs). Dysregulation of HDACs are critical to the development and progression of the majority of tumors. Hence, HDACs inhibitors (HDACis) were developed and now represent a very promising treatment strategy. The use of HDACis as monotherapy has shown very positive pre-clinical results, but clinical trials have had only limited success. However, combinatorial regimens with other cancer drugs have shown synergistic effects both in pre-clinical and clinical studies. At the same time, these combinations have enhanced the efficacy, reduced the toxicity and tumor resistance to therapy. In this review, we will examine examples of HDACis used in combination with other cancer drugs and highlight the synergistic effects observed in recent preclinical and clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Traditionally, cancer is considered a multistep process in which transformational events are mainly associated with genetic changes in oncogenes and tumor suppressor genes (Hanahan and Weinberg, 2011).”
BackgroundA decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871 · cited 1×
“We now know that cancer initiation and progression involves substantial epigenetic abnormalities along with other genetic alterations (Baylin and Jones, 2011; Sandoval and Esteller, 2012).”
BackgroundHaberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
Grignani, F., De Matteis, S., Nervi, C., Tomassoni, L., Gelmetti, V., Cioce, M., Fanelli, M., Ruthardt, M., Ferrara, F. F., Zamir, I., et al. (1998) · Nature · doi:10.1038/35901 · Cited by 1,004 · cited 1×
“For instance, in acute myeloid leukemia PML-RARα, PLZF-RARα, or AML1ETO oncogenic fusion proteins recruit and bind to HDAC complexes increasing co-repressor activity (Gelmetti et al., 1998; Grignani et al., 1998).”
BackgroundTremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
Duffy, A. G., Ulahannan, S. V., Makorova-Rusher, O., Rahma, O., Wedemeyer, H., Pratt, D., Davis, J. L., Hughes, M. S., Heller, T., ElGindi, M., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.10.029 · Cited by 819
Deacetylation of p53 modulates its effect on cell growth and apoptosis
Luo, J., Su, F., Chen, D., Shiloh, A., & Gu, W. (2000) · Nature · doi:10.1038/35042612 · Cited by 818 · cited 1×
“…signaling by silencing tumor suppressor genes transcription or by the alteration of key target genes expression that regulate oncogenic pathways (Luo et al., 2000; Siddiqui et al., 2003; Cras et al., 2007; Godman et al., 2008; Feng et al., 2013), which are more often associated with poor…”
BackgroundHistone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J.-E., Lee, S.-W., Moon, E.-J., Kim, H.-S., Lee, S.-K., Chung, H. Y., et al. (2001) · Nature Medicine · doi:10.1038/86507 · Cited by 731
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Mottamal, M., Zheng, S., Huang, T., & Wang, G. (2015) · Molecules · doi:10.3390/molecules20033898 · Cited by 680
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
Vannini, A., Volpari, C., Filocamo, G., Casavola, E. C., Brunetti, M., Renzoni, D., Chakravarty, P., Paolini, C., De Francesco, R., Gallinari, P., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404603101 · Cited by 638 · cited 1×
“It has been also described that HDAC8 overexpression promotes proliferation in lung, colon, cervical cancer cells (Vannini et al., 2004) and in hepatocellular carcinoma (Wu et al.”
BackgroundHideshima, T., Bradner, J. E., Wong, J., Chauhan, D., Richardson, P., Schreiber, S. L., & Anderson, K. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503221102 · Cited by 593
(2011) · PubMed Central · Cited by 560
A short guide to histone deacetylases including recent progress on class II enzymes
Park, S.-Y., & Kim, J.-S. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0382-4 · Cited by 509
Gelmetti, V., Zhang, J., Fanelli, M., Minucci, S., Pelicci, P. G., & Lazar, M. A. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.12.7185 · Cited by 491
Cancer epigenomics: beyond genomics
Sandoval, J., & Esteller, M. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.02.008 · Cited by 474 · cited 1×
“We now know that cancer initiation and progression involves substantial epigenetic abnormalities along with other genetic alterations (Baylin and Jones, 2011; Sandoval and Esteller, 2012).”
BackgroundTargeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To Succeed
Gryder, B. E., Sodji, Q. H., & Oyelere, A. K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.3 · Cited by 404
Histone deacetylase 8 in neuroblastoma tumorigenesis
Oehme, I., Deubzer, H. E., Wegener, D., Pickert, D., Linke, J.-P., Hero, B., Kopp-Schneider, A., Westermann, F., Ulrich, S. M., von Deimling, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0684 · Cited by 398
Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy
Goldberg, A. L. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350012 · Cited by 367 · cited 1×
“Proteasome Inhibitors The high proliferation of cancer cells requires an elevated protein synthesis rate; this makes them highly dependent on the ubiquitin-proteasome system and, therefore, more susceptible to proteasome inhibitors (Goldberg, 2007).”
BackgroundExpression Profile of Histone Deacetylase 1 in Gastric Cancer Tissues
Choi, J., Kwon, H. J., Yoon, B., Kim, J., Han, S. U., Joo, H. J., & Kim, D. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb02153.x · Cited by 346
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition
Ropero, S., Fraga, M. F., Ballestar, E., Hamelin, R., Yamamoto, H., Boix-Chornet, M., Caballero, R., Alaminos, M., Setien, F., Paz, M. F., et al. (2006) · Nature Genetics · doi:10.1038/ng1773 · Cited by 290
Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks
Knutson, S. K., Chyla, B. J., Amann, J. M., Bhaskara, S., Huppert, S. S., & Hiebert, S. W. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.51 · Cited by 271
The Retinoblastoma-Histone Deacetylase 3 Complex Inhibits PPARγ and Adipocyte Differentiation
Fajas, L., Egler, V., Reiter, R., Hansen, J., Kristiansen, K., Debril, M.-B., Miard, S., & Auwerx, J. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00360-x · Cited by 258
Vogl, D. T., Raje, N., Jagannath, S., Richardson, P., Hari, P., Orlowski, R., Supko, J. G., Tamang, D., Yang, M., Jones, S. S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2526 · Cited by 253 · cited 1×
“The selective inhibition of HDAC6 combined with this proteasome inhibitor triggered dual blockade of aggresomal and proteasomal degradation of protein, and therefore synergistic multiple myeloma cell death (Vogl et al., 2017).”
BackgroundInhibition of histone deacetylases in cancer therapy: lessons from leukaemia
Ceccacci, E., & Minucci, S. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.36 · Cited by 253
Altered sirtuin expression is associated with node-positive breast cancer
Ashraf, N., Zino, S., MacIntyre, A., Kingsmore, D., Payne, A. P., George, W. D., & Shiels, P. G. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603384 · Cited by 248
Stark, M., & Hayward, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4152 · Cited by 237
Role of HDACs in normal and malignant hematopoiesis
Wang, P., Wang, Z., & Liu, J. (2020) · Molecular Cancer · doi:10.1186/s12943-019-1127-7 · Cited by 235 · cited 2×
“in apoptotic pathways have been implicated (Wang et al., 2020).”
BackgroundOsada, H., Tatematsu, Y., Saito, H., Yatabe, Y., Mitsudomi, T., & Takahashi, T. (2004) · International Journal of Cancer · doi:10.1002/ijc.20395 · Cited by 213
Moreno, D. A., Scrideli, C. A., Cortez, M. A. A., De Paula Queiroz, R., Valera, E. T., Da Silva Silveira, V., Yunes, J. A., Brandalise, S. R., & Tone, L. G. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08301.x · Cited by 208 · cited 2×
“In this study, it was shown that all the three HDACs are a promising therapeutic target for the treatment of refractory childhood ALL, although it is not clear whether an individual HDAC is more important over the others in the development of malignancy and in response to treatment.”
BackgroundYee, A. J., Bensinger, W. I., Supko, J. G., Voorhees, P. M., Berdeja, J. G., Richardson, P. G., Libby, E. N., Wallace, E. E., Birrer, N. E., Burke, J. N., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30375-8 · Cited by 203 · cited 2×
“Ricolinostat potentiated the effects of lenalidomide (immunomodulatory drug) and dexamethasone in a phase Ib in patients with multiple myeloma (NCT01583283) (Yee et al., 2016).”
BackgroundHistone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair
Groselj, B., Sharma, N. L., Hamdy, F. C., Kerr, M., & Kiltie, A. E. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.21 · Cited by 184
Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer
Park, C. (2011) · Oncology Reports · doi:10.3892/or.2011.1236 · Cited by 183
HDAC inhibition potentiates immunotherapy in triple negative breast cancer
Terranova-Barberio, M., Thomas, S., Ali, N., Pawlowska, N., Park, J., Krings, G., Rosenblum, M. D., Budillon, A., & Munster, P. N. (2017) · Oncotarget · doi:10.18632/oncotarget.23169 · Cited by 182
Wickström, S. A., Masoumi, K. C., Khochbin, S., Fässler, R., & Massoumi, R. (2010) · The EMBO Journal · doi:10.1038/emboj.2009.317 · Cited by 175 · cited 1×
“Furthermore, HDAC6 and HDAC8 was found to regulate cancer cell migration and invasion via α-tubulin acetylation (Wickstrom et al., 2010; Vanaja et al., 2018).”
BackgroundSankar, S., Theisen, E. R., Bearss, J., Mulvihill, T., Hoffman, L. M., Sorna, V., Beckerle, M. C., Sharma, S., & Lessnick, S. L. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0072 · Cited by 173 · cited 1×
“2 (Sankar et al., 2014) and subsequently enhance the anticancer efficacy.”
BackgroundHistone Deacetylases: A Saga of Perturbed Acetylation Homeostasis in Cancer
Parbin, S., Kar, S., Shilpi, A., Sengupta, D., Deb, M., Rath, S. K., & Patra, S. K. (2014) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155413506582 · Cited by 172
Knox, T., Sahakian, E., Banik, D., Hadley, M., Palmer, E., Noonepalle, S., Kim, J., Powers, J., Gracia-Hernandez, M., Oliveira, V., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42237-3 · Cited by 170 · cited 2×
“A recent study showed that nexturastat A in combination with anti-PD-1 antibodies significantly decreased tumor growth in vivo compared to each agent alone when treating melanoma cells (Knox et al., 2019).”
BackgroundMunster, P. N., Marchion, D., Thomas, S., Egorin, M., Minton, S., Springett, G., Lee, J.-H., Simon, G., Chiappori, A., Sullivan, D., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605293 · Cited by 167
Pathania, R., Ramachandran, S., Mariappan, G., Thakur, P., Shi, H., Choi, J.-H., Manicassamy, S., Kolhe, R., Prasad, P. D., Sharma, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2249 · Cited by 165
Song, C., Zhu, S., Wu, C., & Kang, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.498758 · Cited by 145
Galanis, E., Anderson, S. K., Miller, C. R., Sarkaria, J. N., Jaeckle, K. A., Buckner, J. C., Ligon, K. L., Ballman, K. V., Moore, D. F., Nebozhyn, M., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox161 · Cited by 145
Llópiz, D., Ruiz, M., Villanueva, L., Iglesias, T., Silva, L., Egea, J., Lasarte, J. J., Pivette, P., Trochon-Joseph, V., Vasseur, B., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2283-0 · Cited by 144
Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer
Gray, J. E., Saltos, A., Tanvetyanon, T., Haura, E. B., Creelan, B., Antonia, S. J., Shafique, M., Zheng, H., Dai, W., Saller, J. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1305 · Cited by 141
Erratum: Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma
Sankar, S., Bell, R. N., Stephens, B. J., Zhuo, R., Sharma, S., Bearss, D. J., & Lessnick, S. L. (2016) · Oncogene · doi:10.1038/onc.2016.142 · Cited by 139
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
Banik, D., Moufarrij, S., & Villagra, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092241 · Cited by 133
HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer
Fukumoto, T., Fatkhutdinov, N., Zundell, J. A., Tcyganov, E. N., Nacarelli, T., Karakashev, S. V., Wu, S., Liu, Q., Gabrilovich, D. I., & Zhang, R. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1302 · Cited by 132
Richardson, P. G., Hungria, V. T. M., Yoon, S.-S., Beksac, M., Dimopoulos, M. A., Elghandour, A., Jedrzejczak, W. W., Guenther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2016) · Blood · doi:10.1182/blood-2015-09-665018 · Cited by 131
Moufarrij, S., Srivastava, A., Gomez, S., Hadley, M. M., Palmer, E., Austin, P. T., Chisholm, S., Diab, N., Roche, K. C., Yu, A. Y. C., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-60409-4 · Cited by 127 · cited 2×
“…S eptem ber 2020 |Volum e 11 |A rticle 578011 fgene-11-578011 September 9, 2020 Time: 18:49 # 12 Hontecillas-Prieto et al. HDACis Enhance Anti-tumor Drugs Effects However, this combination only showed a synergistic decrease in tumor burden at week 7 in vivo (Moufarrij et al., 2020).”
BackgroundTaylor, B. S., DeCarolis, P. L., Angeles, C. V., Brenet, F., Schultz, N., Antonescu, C. R., Scandura, J. M., Sander, C., Viale, A. J., Socci, N. D., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0181 · Cited by 124
Knox, T., Sahakian, E., Banik, D., Hadley, M., Palmer, E., Noonepalle, S., Kim, J., Powers, J., Gracia-Hernandez, M., Oliveira, V., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51403-6 · Cited by 118
Deng, S., Hu, Q., Zhang, H., Yang, F., Peng, C., & Huang, C. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1068 · Cited by 116
Malone, C. F., Emerson, C. E., Ingraham, R., Barbosa, W. A., Guerra, S. L., Yoon, H., Liu, L. L., Michor, F., Haigis, M. C., Macleod, K. F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0177 · Cited by 114
HDAC11 is a novel drug target in carcinomas
Deubzer, H. E., Schier, M. C., Oehme, I., Lodrini, M., Haendler, B., Sommer, A., & Witt, O. (2013) · International Journal of Cancer · doi:10.1002/ijc.27876 · Cited by 112
Wu, J., Du, C., Lv, Z., Ding, C., Cheng, J., Xie, H., Zhou, L., & Zheng, S. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2867-7 · Cited by 108
Thal, M. A., Krishnamurthy, P., Mackie, A. R., Hoxha, E., Lambers, E., Verma, S. K., Ramirez, V., Qin, G., Losordo, D. W., & Kishore, R. (2012) · Circulation Research · doi:10.1161/circresaha.112.270462 · Cited by 105 · cited 1×
“, 2012), cardiovascular (Thal et al., 2012; Xu et al., 2013) and inflammatory diseases (Kim et al.”
BackgroundMishima, Y., Santo, L., Eda, H., Cirstea, D., Nemani, N., Yee, A. J., O'Donnell, E., Selig, M. K., Quayle, S. N., Arastu‐Kapur, S., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13315 · Cited by 103
Aggarwal, R. R., Thomas, S., Pawłowska, N., Bartelink, I. H., Grabowsky, J. A., Jahan, T. M., Cripps, A., Harb, A., Leng, J. X., Reinert, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.5350 · Cited by 103
Galloway, T. J., Wirth, L. J., Colevas, A. D., Gilbert, J., Bauman, J. E., Saba, N. F., Raben, D., Mehra, R., Ma, A. W., Atoyan, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2820 · Cited by 102 · cited 1×
“A Phase I Study combined CUDC-101 with chemoradiation in head and neck squamous cell carcinoma patients at biologically efficacious doses was tolerated (Galloway et al., 2015).”
BackgroundAmengual, J. E., Johannet, P. M., Lombardo, M., Zullo, K. M., Hoehn, D., Bhagat, G., Scotto, L., Jirau-Serrano, X., Radeski, D., Heinen, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3068 · Cited by 100 · cited 1×
“Similar results were obtained with the same combination in vitro and in vivo, which caused a significant delay in tumor growth and prolonged overall survival in a xenograft mice model (Amengual et al., 2015).”
ResultGenome-Wide Histone Acetylation Is Altered in a Transgenic Mouse Model of Huntington's Disease
McFarland, K. N., Das, S., Sun, T. T., Leyfer, D., Xia, E., Sangrey, G. R., Kuhn, A., Luthi-Carter, R., Clark, T. W., Sadri-Vakili, G., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041423 · Cited by 94
Godman, C. A., Joshi, R., Tierney, B. R., Greenspan, E., Rasmussen, T. P., Wang, H.-W., Shin, D.-G., Rosenberg, D. W., & Giardina, C. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.10.6561 · Cited by 87
Targeting epigenetic regulations in cancer
Ning, B., Li, W., Zhao, W., & Wang, R. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv116 · Cited by 84
Histone Deacetylase Inhibition Sensitizes PD1 Blockade–Resistant B-cell Lymphomas
Wang, X., Waschke, B. C., Woolaver, R. A., Chen, Z., Zhang, G., Piscopio, A. D., Liu, X., & Wang, J. H. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0875 · Cited by 83 · cited 2×
“The results from combined OKI179/anti-PD1 antibody treatment in lymphomas showed a synergistic effect compared with more limited effects in monotherapy (Wang et al., 2019).”
BackgroundResultHalsall, J. A., & Turner, B. M. (2016) · BioEssays · doi:10.1002/bies.201600070 · Cited by 83
Siddiqui, H., Solomon, D. A., Gunawardena, R. W., Wang, Y., & Knudsen, E. S. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.21.7719-7731.2003 · Cited by 78
Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma
Adams, H., Fritzsche, F. R., Dirnhofer, S., Kristiansen, G., & Tzankov, A. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728221003796609 · Cited by 78
DuBois, S. G., Groshen, S. G., Park, J. R., Haas-Kogan, D. A., Yang, X., Geier, E. G., Chen, E., Giacomini, K., Weiss, B., Cohn, S. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3240 · Cited by 75 · cited 2×
“Preclinical Tanaka et al., 2017 131IMetaiodobenzylguanidine Radiotherapy Neuroblastoma Good outcome Phase I DuBois et al., 2015; NCT01019850 Chemoradiation therapy Radiotherapy Head and neck squamous carcinoma Combination safe and effective.”
BackgroundVanaja, G. R., Ramulu, H. G., & Kalle, A. M. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0231-4 · Cited by 74 · cited 2×
“For example, overexpressed of HDAC8 in neuroblastoma, cervical cancer and esophageal squamous cell carcinoma has been significantly correlated with poor prognosis in patients (Oehme et al., 2009; Vanaja et al., 2018).”
BackgroundAlhazzazi, T. Y., Kamarajan, P., Xu, Y., Ai, T., Chen, L., Verdin, E. M., & Kapila, Y. L. (2016) · PubMed · Cited by 74
Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer
Chan, E. W., Arlinghaus, L. R., Cardin, D. B., Goff, L. W., Berlin, J. D., Parikh, A. A., Abramson, R. G., Yankeelov, T. E., Hiebert, S. W., Merchant, N. B., et al. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.04.013 · Cited by 72
Santoro, V., Jia, R., Thompson, H., Nijhuis, A. M., Jeffery, R. E., Kiakos, K., Silver, A. R., Hartley, J. A., & Hochhauser, D. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv394 · Cited by 69
Self-citationNeuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival
Thole, T. M., Lodrini, M., Fabian, J., Wuenschel, J., Pfeil, S., Hielscher, T., Kopp-Schneider, A., Heinicke, U., Fulda, S., Witt, O., et al. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.49 · Cited by 67 · cited 1×
“Moreover, HDAC11 regulates cell cycle, apoptosis and survival in neuroblastoma cells lines (Thole et al., 2017).”
BackgroundHistone Deacetylase 3 Mediates Allergic Skin Inflammation by Regulating Expression of MCP1 Protein
Kim, Y., Kim, K., Park, D., Lee, E.-M., Lee, H., Lee, Y., Choe, J., & Jeoung, D. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.348284 · Cited by 67
Mackintosh, C., García-Domínguez, D. J., Ordóñez, J. L., Ginel-Picardo, A., Smith, P. G., Sacristán, M. P., & de Álava, E. (2012) · Oncogene · doi:10.1038/onc.2012.153 · Cited by 66 · cited 1×
“WEE1 is a kinase that has been linked to G2/M arrest and drugs cytotoxic action (Mackintosh et al., 2013).”
BackgroundSelf-citationZhang, L., Zhang, Y., Mehta, A. R., Boufraqech, M., Davis, S. R., Wang, J., Tian, Z., Yu, Z., Boxer, M. B., Kiefer, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3268 · Cited by 61
Zibelman, M. R., Wong, Y., Devarajan, K., Malizzia, L., Corrigan, A., Olszanski, A. J., Denlinger, C. S., Roethke, S. K., Tetzlaff, C. H., & Plimack, E. R. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0261-3 · Cited by 60
Haydn, T., Metzger, E., Schüle, R., & Fulda, S. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.239 · Cited by 60 · cited 2×
“Preclinical Haydn et al., 2017 Pembrolizumab Immunotherapy Non-small lung cancer Preliminary anti-tumor activity.”
BackgroundMa, W., Zhao, X., Wang, K., Liu, J., & Huang, G. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1480281 · Cited by 59
Cosenza, M., Civallero, M., Marcheselli, L., Sacchi, S., & Pozzi, S. (2017) · APOPTOSIS · doi:10.1007/s10495-017-1364-4 · Cited by 54 · cited 2×
“Preclinical Cosenza et al., 2017 Oxaliplatin Alkylant agent Colorectal cancer Downregulation of p-ERK and p-AKT and induction of cell apoptosis via activation caspase-3 and elevation of the Bak to Bcl-xL ratio.”
BackgroundKaufman, J. L., Mina, R., Jakubowiak, A. J., Zimmerman, T. L., Wolf, J. J., Lewis, C. M., Gleason, C. L., Sharp, C., Martin, T. G., Heffner, L. T., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-018-0154-8 · Cited by 54
Persky, D. O., Li, H., Rimsza, L. M., Barr, P. M., Popplewell, L. L., Bane, C. L., Gehr, A. V., LeBlanc, M. L., Fisher, R. I., Smith, S. M., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.25010 · Cited by 53
Teknos, T. N., Grecula, J. C., Agrawal, A., Old, M. O., Ozer, E., Carrau, R., Kang, S.-Y., Rocco, J. W., Blakaj, D. M., Diavolitsis, V. M., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0696-4 · Cited by 53 · cited 1×
“Similarly, vorinostat in combination with chemoradiation therapy in phase I trial of neck squamous cell carcinoma patients was found to be safe and highly effective (Teknos et al., 2019).”
BackgroundTerranova-Barberio, M., Pecori, B., Roca, M. S., Imbimbo, S., Bruzzese, F., Leone, A., Muto, P., Delrio, P., Avallone, A., Budillon, A., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0647-5 · Cited by 52
Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer
Gerber, D. E., Boothman, D. A., Fattah, F. J., Dong, Y., Zhu, H., Skelton, R. A., Priddy, L. L., Vo, P., Dowell, J. E., Sarode, V. R., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.10.008 · Cited by 51
Hainsworth, J. D., Daugaard, G., Lesimple, T., Hübner, G., Greco, F. A., Stahl, M., Büschenfelde, C. M. Z., Allouache, D., Penel, N., Knoblauch, P., et al. (2015) · Cancer · doi:10.1002/cncr.29229 · Cited by 51
Bruyer, A., Maes, K., Herviou, L., Kassambara, A., Seckinger, A., Cartron, G., Reme, T. X., Robert, N., Requirand, G., Boireau, S., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0025-x · Cited by 50
Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor
North, B. J., Almeciga-Pinto, I., Tamang, D., Yang, M., Jones, S. S., & Quayle, S. N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173507 · Cited by 49 · cited 2×
“This combination also improved cytotoxicity by decreasing apoptosis and cell cycle arrest (North et al., 2017).”
BackgroundDecreased expression of histone deacetylase 10 predicts poor prognosis of gastric cancer patients.
Jin, Z., Jiang, W., Jiao, F., Guo, Z., Hu, H. X., Wang, L., & Wang, L. (2014) · PubMed · Cited by 48
Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells
Grabarska, A., Łuszczki, J. J., Nowosadzka, E., Gumbarewicz, E., Jeleniewicz, W., Dmoszyńska‐Graniczka, M., Kowalczuk, K., Kupisz, K., Polberg, K., & Stepulak, A. (2016) · Journal of Cancer · doi:10.7150/jca.16655 · Cited by 46
Heijkants, R. C., Willekens, K., Schoonderwoerd, M. J. A., Teunisse, A. F. A. S., Nieveen, M. C., Radaelli, E., Hawinkels, L., Marine, J., & Jochemsen, A. G. (2017) · Oncotarget · doi:10.18632/oncotarget.23485 · Cited by 46
ASGAR, M. A., Senawong, G., Sripa, B., & Senawong, T. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3240 · Cited by 43
Grošelj, B., Ruan, J.-L., Scott, H. E., Gorrill, J., Nicholson, J., Kelly, J., Anbalagan, S., Thompson, J. M., Stratford, M. R. L., Jevons, S. J., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0011 · Cited by 42
Feng, D., Wu, J., Tian, Y., Zhou, H., Zhou, Y. Y., Hu, W., Zhao, W., Wei, H., Ling, B., & Ma, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080657 · Cited by 42
Liffers, K., Kolbe, K., Westphal, M., Lamszus, K., & Schulte, A. (2016) · Targeted Oncology · doi:10.1007/s11523-015-0372-y · Cited by 41
Saijo, K., Imamura, J., Narita, K., Oda, A., Shimodaira, H., Katoh, T., & Ishioka, C. (2014) · Cancer Science · doi:10.1111/cas.12585 · Cited by 41 · cited 1×
“Romidepsin and its analogs, FK-A5 and FK-A11, have showed a dual inhibition on HDACs and PI3K resulting in stronger cytotoxic effects in a panel of human cancer cell lines (Saijo et al., 2015).”
BackgroundComparison of Radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in Pancreatic Cancer Cells
Moertl, S., Payer, S., Kell, R., Winkler, K., Anastasov, N., & Atkinson, M. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133259 · Cited by 41
Cras, A., Darsin-Bettinger, D., Balitrand, N., Cassinat, B., Soulié, A., Toubert, M.-E., Delva, L., & Chomienne, C. (2007) · Oncogene · doi:10.1038/sj.onc.1210178 · Cited by 39 · cited 1×
“…silencing tumor suppressor genes transcription or by the alteration of key target genes expression that regulate oncogenic pathways (Luo et al., 2000; Siddiqui et al., 2003; Cras et al., 2007; Godman et al., 2008; Feng et al., 2013), which are more often associated with poor outcomes in patients.”
BackgroundLee, B. B., Kim, Y., Kim, D., Cho, E. Y., Han, J., Kim, H. K., Shim, Y. M., & Kim, D. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14194 · Cited by 39 · cited 2×
“Preclinical Lee et al., 2019 Frontiers in G enetics |w w w .frontiersin.org 11 S eptem ber 2020 |Volum e 11 |A rticle 578011 fgene-11-578011 September 9, 2020 Time: 18:49 # 12 Hontecillas-Prieto et al. HDACis Enhance Anti-tumor Drugs Effects However, this combination only showed a synergistic…”
BackgroundTanaka, N., Patel, A. A., Tang, L., Silver, N. L., Lindemann, A., Takahashi, H., Jaksik, R., Rao, X., Kalu, N. N., Chen, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0947 · Cited by 39 · cited 2×
“A preclinical study showed a synergistic effect between vorinostat and AZD1775 (WEE1 inhibitor) in vitro and in vivo in head and neck squamous tumor cells expressing high-risk mutant p53 (Tanaka et al., 2017).”
BackgroundLee, D. H., Won, H.-R., Ryu, H.-W., Han, J. M., & Kwon, S. H. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4405 · Cited by 38 · cited 2×
“Preclinical Lee et al., 2018 Bortezomib and dexamethasone Proteasome inhibitors Multiple myeloma Autophagic protein degradation.”
BackgroundZhang, H., Dong, L., Chen, Q., Kong, L., Meng, B., Wang, H., Fu, K., Wang, X., Pan‐Hammarström, Q., Wang, P., et al. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.01.025 · Cited by 37
Breaking down the Contradictory Roles of Histone Deacetylase SIRT1 in Human Breast Cancer
Rifai, K. T., Idrissou, M., Penault-Llorca, F. M., Bignon, Y., & Bernard-Gallon, D. J. (2018) · Cancers · doi:10.3390/cancers10110409 · Cited by 35 · cited 1×
“However, the efficacy of this Sirt1 inhibitor requires further investigation and subsequent review (Rifai et al., 2018).”
BackgroundGurbani, S. S., Yoon, Y., Weinberg, B. D., Salgado, E., Press, R. H., Cordova, J. S., Ramesh, K. K., Liang, Z., Vega, J. E. V., Voloschin, A. D., et al. (2019) · Tomography · doi:10.18383/j.tom.2018.00031 · Cited by 35
Chaiyawat, P., Pruksakorn, D., Phanphaisarn, A., Teeyakasem, P., Klangjorhor, J., & Settakorn, J. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.125 · Cited by 30
Amengual, J. E., Prabhu, S. A., Lombardo, M., Zullo, K. M., Johannet, P. M., Gonzalez, Y., Scotto, L., Serrano, X. O. J., Wei, Y., Duong, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2022 · Cited by 30
Histone deacetylase inhibition reduces cardiac connexin43 expression and gap junction communication
Xu, Q., Lin, X., Andrews, L. E., Patel, D., Lampe, P. D., & Veenstra, R. D. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00044 · Cited by 29 · cited 1×
“…of HDACs has been implicated in different human diseases such as nervous system (McFarland et al., 2012), cardiovascular (Thal et al., 2012; Xu et al., 2013) and inflammatory diseases (Kim et al., 2012; Zhang et al., 2017b), and in cancer disease where their role has been explored…”
BackgroundGarcía-Domínguez, D. J., Hontecillas‐Prieto, L., Rodríguez‐Núñez, P., Pascual‐Pasto, G., Vilà-Ubach, M., García-Mejías, R., Robles, M. J., Tirado, Ò. M., Mora, J., Carcaboso, A. M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25829 · Cited by 29 · cited 2×
“For example, the combination of a LSD1 inhibitor (HCI-2509) and SAHA exhibited a synergistic inhibition on tumor growth and enhanced apoptosis in Ewing sarcoma cell lines and in patient-derived xenograft mouse models (Garcia-Dominguez et al., 2018).”
BackgroundSelf-citationHuang, Z., Peng, S., Knoff, J. S., Lee, S. Y., Yang, B. K., Wu, T.-C., & Hung, C. (2015) · Journal of Biomedical Science · doi:10.1186/s12929-014-0111-1 · Cited by 29 · cited 2×
“In fact, the combined treatment SAHA and a proteasome inhibitor, bortezomib, enhances the antitumor effects and immune properties of cervical cancer cells, both in vitro and in vivo (Huang et al., 2015).”
BackgroundGumbarewicz, E., Łuszczki, J. J., Wawruszak, A., Dmoszyńska‐Graniczka, M., Grabarska, A., Jarząb, A., Polberg, K., & Stepulak, A. (2016) · PubMed Central · Cited by 28
Huang, F.-I., Wu, Y.-W., Sung, T.-Y., Liou, J., Lin, M., Pan, S., & Yang, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00249 · Cited by 27
Ji, M., Li, Z., Lin, Z., & Chen, L. (2018) · Europe PMC (PubMed Central) · Cited by 26
Martile, M. D., Desideri, M., Tupone, M. G., Buglioni, S., Antoniani, B., Mastroiorio, C., Falcioni, R., Ferraresi, V., Baldini, N., Biagini, R., et al. (2018) · Oncogenesis · doi:10.1038/s41389-018-0026-x · Cited by 25 · cited 3×
“Preclinical Di Martile et al., 2018 OKI-179 Anti-PD1 antibody Immunotherapy Lymphoma HDACis sensitize lymphomas to PD1-blokage by enhance tumor immunogenicity.”
BackgroundInfluentialHolkova, B., Kmieciak, M., Bose, P., Yazbeck, V. Y., Barr, P. M., Tombes, M. B., Shrader, E., Weir-Wiggins, C., Rollins, A. D., Cebula, E., et al. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1075019 · Cited by 24
Zhang, H., Li, X., Zhang, Q., Yang, F., Chu, X., Zhang, D., Wang, L.-W., & Gong, Z. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6290 · Cited by 18
Ji, J., Valdez, B. C., Li, Y., Liu, Y., Teo, E. C.-Y., Nieto, Y. L., Champlin, R. E., & Andersson, B. S. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.03.001 · Cited by 8
Cited by
Lee, Y. T., Tan, Y. J., & Oon, C. E. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.09.010 · Cited by 249
Histone Deacetylases 1 and 2 in Memory Function
Pao, P.-C., & Tsai, L.-H. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00775 · Cited by 34
Metadata
- Authors
- Hontecillas-Prieto, L., Flores-Campos, R., Silver, A., de Álava, E., Hajji, N., & García-Domínguez, D. J.
- Venue
- Frontiers in Genetics
- Publisher
- Frontiers Media SA
- Published
- 2020-09-11
- Volume
- 11
- Pages
- 578011-578011
- ISSN
- 1664-8021 (ISSN-L)
- OpenAlex
- W3086678038
- Cited by
- 177
- References
- 117
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.